Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | PLD1 | Q13393 | 7/20 | 0.34 |
| ▸ | PLD2 | O14939 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | DRD3 | P35462 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2871600 | 0.92 | ALDH1A1 (0.37) | NPSR1TSHRLMNAHTR1A | |
| SCHEMBL2856576 | 0.92 | NPSR1 (0.37) | NPSR1MAOAPLD1PLD2SMN1; SMN2 | |
| SCHEMBL2863796 | 0.90 | NPSR1 (0.33) | NPSR1PLD1PLD2TSHR | |
| SCHEMBL2863395 | 0.87 | HTR3A (0.40) | NPSR1PLD1PLD2LMNACD274 | |
| SCHEMBL2868076 | 0.87 | SMN1; SMN2 (0.37) | NPSR1MAOATSHRSMN1; SMN2DRD3 | |
| SCHEMBL2858492 | 0.80 | NPSR1 (0.37) | NPSR1TSHRLMNA | |
| SCHEMBL2867845 | 0.79 | CYP3A4 (0.46) | NPSR1TSHRLMNA | |
| SCHEMBL2865812 | 0.79 | NPSR1 (0.51) | NPSR1SMN1; SMN2 | |
| SCHEMBL2858188 | 0.79 | L3MBTL1 (0.44) | NPSR1TSHRLMNA | |
| SCHEMBL2863108 | 0.79 | L3MBTL1 (0.44) | NPSR1TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795267-B2 | Bicyclic piperazine compound having TGR23 antagonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-14 | — | — | US | disclosed |
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-29 | — | — | US | disclosed |
| EP-1661898-A1 | BICYCLIC PIPERAZINE COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2006-05-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072865-A1 | Bicyclic piperazine compound and use thereof | GPR3, FFAR3, LPAR3 | NPSR1 211/4885MAOA 2997/4885PLD1 1582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.